Lifecore Biomedical partners with Nirsum Labs for opioid use disorder treatment development
- Lifecore Biomedical has been selected by Nirsum Labs to provide CDMO services for NRS-033, a treatment for opioid and alcohol use disorders.
- The agreement includes technology transfer, process assessment, and method validation for the fill and finish of NRS-033.
- NRS-033 is entering Phase 2 clinical development, with Lifecore providing filled syringes for clinical use.
- The collaboration is part of Nirsum's NIH-funded development program for NRS-033.
Read more
